266 related articles for article (PubMed ID: 34403682)
21. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.
Shen D; Chen W; Zhu J; Wu G; Shen R; Xi M; Sun H
Eur J Med Chem; 2020 Mar; 190():112117. PubMed ID: 32061959
[TBL] [Abstract][Full Text] [Related]
23. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
24. SHP2: The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis.
Chang CJ; Lin CF; Chen BC; Lin PY; Chen CL
IUBMB Life; 2022 Feb; 74(2):131-142. PubMed ID: 34590785
[TBL] [Abstract][Full Text] [Related]
25. Strategies to overcome drug resistance using SHP2 inhibitors.
Liu M; Gao S; Elhassan RM; Hou X; Fang H
Acta Pharm Sin B; 2021 Dec; 11(12):3908-3924. PubMed ID: 35024315
[TBL] [Abstract][Full Text] [Related]
26. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
[TBL] [Abstract][Full Text] [Related]
27. Targeted Degradation of the Oncogenic Phosphatase SHP2.
Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
[TBL] [Abstract][Full Text] [Related]
28. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.
Ruess DA; Heynen GJ; Ciecielski KJ; Ai J; Berninger A; Kabacaoglu D; Görgülü K; Dantes Z; Wörmann SM; Diakopoulos KN; Karpathaki AF; Kowalska M; Kaya-Aksoy E; Song L; van der Laan EAZ; López-Alberca MP; Nazaré M; Reichert M; Saur D; Erkan MM; Hopt UT; Sainz B; Birchmeier W; Schmid RM; Lesina M; Algül H
Nat Med; 2018 Jul; 24(7):954-960. PubMed ID: 29808009
[TBL] [Abstract][Full Text] [Related]
29. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.
Agazie YM; Movilla N; Ischenko I; Hayman MJ
Oncogene; 2003 Oct; 22(44):6909-18. PubMed ID: 14534538
[TBL] [Abstract][Full Text] [Related]
30. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
Song Y; Zhao M; Wu Y; Yu B; Liu HM
Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
[TBL] [Abstract][Full Text] [Related]
31. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling.
Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A
Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865
[TBL] [Abstract][Full Text] [Related]
32. Altered glucose homeostasis in mice with liver-specific deletion of Src homology phosphatase 2.
Matsuo K; Delibegovic M; Matsuo I; Nagata N; Liu S; Bettaieb A; Xi Y; Araki K; Yang W; Kahn BB; Neel BG; Haj FG
J Biol Chem; 2010 Dec; 285(51):39750-8. PubMed ID: 20841350
[TBL] [Abstract][Full Text] [Related]
33. A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism.
Tao Y; Xie J; Zhong Q; Wang Y; Zhang S; Luo F; Wen F; Xie J; Zhao J; Sun X; Long H; Ma J; Zhang Q; Long J; Fang X; Lu Y; Li D; Li M; Zhu J; Sun B; Li G; Diao J; Liu C
J Biol Chem; 2021; 296():100538. PubMed ID: 33722610
[TBL] [Abstract][Full Text] [Related]
34. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
[TBL] [Abstract][Full Text] [Related]
35. A patent review of SHP2 allosteric inhibitors (2018-present).
Petrocchi A; Ciammaichella A
Expert Opin Ther Pat; 2024 May; 34(5):383-396. PubMed ID: 38842843
[TBL] [Abstract][Full Text] [Related]
36. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
37. Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2.
Zhang SQ; Tsiaras WG; Araki T; Wen G; Minichiello L; Klein R; Neel BG
Mol Cell Biol; 2002 Jun; 22(12):4062-72. PubMed ID: 12024020
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2.
Zhang RY; Yu ZH; Chen L; Walls CD; Zhang S; Wu L; Zhang ZY
J Biol Chem; 2020 May; 295(18):6187-6201. PubMed ID: 32188694
[TBL] [Abstract][Full Text] [Related]
39. Proteolysis-targeting chimera molecules targeting SHP2.
Yu D; Zheng M; Liu Y; Chen L; Li H
Future Med Chem; 2022 Apr; 14(8):587-600. PubMed ID: 35297283
[TBL] [Abstract][Full Text] [Related]
40. Identification of demethylincisterol A
Chen C; Liang F; Chen B; Sun Z; Xue T; Yang R; Luo D
Eur J Pharmacol; 2017 Jan; 795():124-133. PubMed ID: 27939989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
